Avirmax Biopharma

News Room

Oct 18,2021

Avirmax Presents Simple and Robust Technology Platform for AAV Production
Presentation Detailing Bac-to-AAV Sf9 Platform High-Titer, Downstream Purity and Safety

HAYWARD, Calif., [October 18, 2021]—Dr. Shawn (Shengjiang) Liu, President and CEO of Avirmax, Inc., a San Francisco Bay Area Gene Therapy company, presented “A Simple and Robust rAAV Manufacturing System to Achieve High Titer and Quality Gene Therapy Vectors” during the BioProcessing International Conference at the Boston Convention and Exhibition Center and online.   

Avirmax believes genetic medicine is becoming an increasing trend of biopharmaceutical development and expected to be the future medicine due to its offering not only in the cure for rare genetic disorders but also the cure and/or reduced dosing frequency for treatment of chronic diseases. Dr. Liu presents that among various types of viral vector system, Avirmax has demonstrated it can achieve these goals through its proprietary downstream process technology which is simple and robust, yields high titers up to 1E+15 vg/L, high quality of rAAV (high full/empty ratio), 80-100 vg/TCID50 and high purity at <1 ng of host cell protein per dose, if Bac-to-AAV Sf9 insect cells system were used.  

The manufacturing technology is applicable to various serotypes of AAV vectors.  The downstream process is applicable to human derived cell culture AAV production system i.e., HEK293 cells. Avirmax is building an internal cGMP facility for manufacturing clinical material to support both internal and external client projects.

For external manufacturing interest, please contact:

Aaron Boyer – Business Development
Email:[email protected]

About Avirmax, Inc.

Avirmax, Inc. a Delaware Corporation based in San Francisco Bay Area, is dedicated to innovate, develop, and manufacture adeno-associated virus (AAV) vector mediated biotherapeutics using its proprietary protein therapeutics and BAC-to-AAV technologies. The Avirmax Adeno-associated Vector Innovation Platform (AAVIP) enables us to become a powerhouse of rAAV therapeutics due to its very infectious AAV vectors with high titers at production and enhanced expression of gene of interest (GOI) in target cells. Our ultimate goal is to deliver patients with the effective, safe, long-acting AAV-mediated biotherapeutics in the most affordable and accessible manner.

Avirmax, Inc is dedicated to innovate and develop novel technologies to address current challenges in viral vector production using its state-of-the-art AAV bioprocess technologies in combination with Virovek’s BAC-to-AAV insect system. Avirmax has established robust rAAV vector production technologies for small and large-scale applications using Sf9-Baculovirus system.

Find out more information on our website www.avirmax.com

Avirmax, Inc. Forward-Looking Statements

This press release contains forward-looking statements based on current assumptions and forecasts made by Avirmax management. These forward-looking statements, including statements relating to expectations, plans and prospects regarding the success of formal content included or assumed from presentations regarding new discoveries and advances in viral vector development and manufacturing as an opportunity to advance innovation in the hope of generating new therapies.  Although we believe our plans, intentions, expectations, strategies and prospects as reflected in or suggested by these forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved.  Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including but not limited to, the success of our development and manufacturing technologies to produce therapeutics and the success of our operations.  Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time.  Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.